Open AccessOptimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study
Author(s) -
Paolo Denti,
Roeland E Wasmann,
Annelies Van Rie,
Jana Winckler,
Adrie Bekker,
Helena Rabie,
Anneke C. Hesseling,
Louvina E van der Laan,
Carmen González-Martínez,
Heather J. Zar,
Gerry Davies,
Lubbe Wiesner,
Elin M. Svensson,
Helen McIlleron
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab908
Subject(s) - pyrazinamide , medicine , isoniazid , rifampicin , dosing , fixed dose combination , pharmacokinetics , pharmacology , tuberculosis , population , pathology , environmental health
In 2010, the World Health Organization (WHO) revised dosing guidelines for treatment of childhood tuberculosis. Our aim was to investigate first-line antituberculosis drug exposures under these guidelines, explore dose optimization using the current dispersible fixed-dose combination (FDC) tablet of rifampicin/isoniazid/pyrazinamide; 75/50/150 mg, and suggest a new FDC with revised weight bands.